文献速递胃肠动力与功能性疾病

成人粪便失禁:新疗法

Fecal Incontinence in Adults: New Therapies.
PubMed 文献 · Am J Gastroenterol · 2025-03-13

粪便失禁是反复发生的不自主排粪,全球患病率约8%,显著影响身心状况并带来经济负担。危险因素包括高龄、腹泻、产科或肛门直肠手术导致的括约肌损伤、盆腔器官脱垂等。治疗从饮食调整、纤维补充、止泻药和物理治疗等保守措施开始,进阶选择包括生物反馈、肛门周围注射膨胀剂、屏障装置、经肛门灌洗和骶神经调节;部分神经刺激疗法在对照试验中未优于安慰剂。

要点

  • 粪便失禁全球患病率约8%,危险因素含高龄、腹泻、括约肌损伤、直肠脱垂、炎症性肠病和神经系统疾病。
  • 保守治疗包括饮食调整、纤维补充、止泻药和物理治疗,针对症状个体化并严格执行时患者常获益。
  • 骶神经调节是粪便失禁首选手术治疗;肛门括约肌成形术因长期疗效有限通常保留给年轻产科括约肌缺损患者。

核心结论

  • 尽管对粪便失禁影响的认识、诊断技术和治疗选择已有进步,管理仍不一致,可能因对可用疗法知晓有限。
  • 经肛门灌洗可考虑用于神经源性肠道和粪便潴留患者,以助直肠清洁和预防粪便失禁。
  • 经隧骶磁刺激在非对照试验中有效,但需假刺激对照试验。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • 粪便失禁全球患病率约8%。
  • 非侵入性肛门电刺激和经皮胫神经刺激在对照试验中未优于安慰剂。
  • 经隧骶磁刺激在非对照试验中有效。
  • 自体肌细胞注射至肛门外括约肌在小规模非对照试验中显示前景,但在多数对照试验中未产生显著结果。

关键数值与推荐

  • 保守治疗包括饮食调整、纤维补充、止泻药和物理治疗,尤其针对特定症状个体化并严格执行时患者常获益。
  • 下一层次选择包括肛门直肠生物反馈治疗、肛门周围可注射膨胀剂右旋糖酐或肛门/阴道屏障装置,如患者耐受可有效。
  • 经肛门灌洗可考虑用于神经源性肠道和粪便潴留患者。
  • 骶神经调节是粪便失禁首选手术治疗。
  • 肛门括约肌成形术因长期疗效有限,通常保留给年轻产科肛门括约肌缺损患者;结肠造口被视为最后手段。

临床怎么用

  • 对粪便失禁患者,可先采用饮食调整、纤维补充、止泻药和物理治疗等保守措施,尤其针对特定症状个体化并严格执行。
  • 保守治疗不佳者可考虑肛门直肠生物反馈、肛门周围注射右旋糖酐或肛门/阴道屏障装置。
  • 神经源性肠道和粪便潴留患者可考虑经肛门灌洗以助直肠清洁和预防粪便失禁。
  • 骶神经调节是首选手术治疗;肛门括约肌成形术通常保留给年轻产科括约肌缺损患者;结肠造口为最后手段。

局限性

  • 经隧骶磁刺激仅在非对照试验中显示有益,需假刺激对照试验。
  • 自体肌细胞注射至肛门外括约肌在小规模非对照试验中显示前景,但在多数对照试验中未产生显著结果。
  • 肛门括约肌成形术长期疗效有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fecal incontinence (FI) is the involuntary and recurrent loss of stool. FI significantly affects both physical and social well-being, while imposing a substantial economic burden. The global prevalence of FI is approximately 8%. Risk factors include advanced age, diarrhea, anal sphincter damage from obstetric trauma or anorectal surgery, pelvic floor abnormalities (such as rectal prolapse), inflammatory bowel disease, and neurological conditions. Despite greater understanding of the impact of FI and advances in diagnostic techniques and treatment options, management remains inconsistent, likely because of limited awareness of available therapies. Patients often benefit from conservative treatments, including dietary modifications, fiber supplementation, antidiarrheal agents, and physical therapy, especially when these are tailored to specific symptoms and rigorously applied. Next level options include anorectal biofeedback therapy, the perianal injectable bulking agent dextranomer, or anal/vaginal barrier devices, which can be effective for patients if tolerated. Transanal irrigation may be considered for patients with neurogenic bowel and fecal retention to aid in rectal cleansing and prevent FI. Sacral neuromodulation is the preferred surgical treatment of FI. Noninvasive anal electrical and percutaneous tibial nerve stimulation are not superior to placebo in controlled trials. Translumbosacral magnetic stimulation was beneficial in an uncontrolled trial; sham-controlled trials are necessary. Owing to limited long-term efficacy, anal sphincteroplasty is typically reserved for younger patients with obstetric anal sphincter defects. Colostomy is considered a last resort. Injection of autologous muscle cells into the external anal sphincter has shown promise in small uncontrolled trials, although it has not yielded significant results in most controlled trials.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Blackett JW, Bharucha AE. Fecal Incontinence in Adults: New Therapies. Am J Gastroenterol. 2025. PMID: 40079456. doi:10.14309/ajg.0000000000003413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。